Back to search results

A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies

Abroad (travel likely)RecruitingPHASE1

Conditions

Leukemia · AML · MDS · AML (Acute Myelogenous Leukemia) · MDS (Myelodysplastic Syndrome)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • The First Affiliated Hospital of Nanchang University, Nanchang, China

    Contact: Study coordinator (Fei Li, MD) · yx021021@sina.com · +8613970038386

  • The Haematology Hospital of the Chinese Academy of Medical Sciences, Tianjin, China

    Contact: Study coordinator (Jianxiang Wang, MS) · wangjx@medmail.com.cn · 86-22-23909120
    Junyuan Qi, MS (Sub-investigator)

  • Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    Contact: Study coordinator (Dengju Li, MD) · lidengju@163.com · +8613237100810
Study leads

  • Jianxiang Wang, MS

    Principal Investigator

    The Haematology Hospital of the Chinese Academy of Medical Sciences

View source on ClinicalTrials.gov(opens in a new tab)